The Deutsche Diabetes Forschungsgesellschaft e.V.

Quick facts

Phase 2 pipeline

• AP-325 · Diabetes
  AP-325 is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• The Deutsche Diabetes Forschungsgesellschaft e.V. portfolio CI brief
• The Deutsche Diabetes Forschungsgesellschaft e.V. pipeline updates RSS